SASylvie Alonso

Sylvie Alonso

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sylvie Alonso has a total of 383 co-authors. Here are the top co-authors by number of shared publications:

  • Vincent Tak Kwong Chow

    Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Kent Ridge, Singapore 117545, Singapore

    8 shared publications
  • Ze Qin Lim

    Infectious Diseases Translational Research Programme; Department of Microbiology and Immunology; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

    8 shared publications
  • Qing Yong Ng

    Infectious Diseases Translational Research Programme; Department of Microbiology and Immunology; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

    6 shared publications
  • Eng Lee Tan

    Department of Pediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

    5 shared publications
  • Justin Jang Hann Chu

    Biosafety Level 3 Core Facility, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

    5 shared publications
  • Kevin Pethe

    Singapore Centre for Environmental Life Sciences Engineering, School of Biological Sciences, Nanyang Technological University, Singapore, Singapore

    5 shared publications

Latest Publications

  • Open Access

    CD137L adjuvanted vaccine increases antigen-specific T-cell responses but impacts antigen-specific humoral responses

    by Kanin Salao, Ming Xuan Lim, Daryl Zhang Wei Lee, Jaz Linn Ng, Jia Le Lin, Wanzhen Lu, Estelle Goh, Emily Nickles, Herbert Schwarz, Sylvie Alonso, et al.

    CD137 engagement through CD137 ligand (CD137L) or agonistic antibodies has shown promising results in cancer immunotherapy. Here, we explored CD137L as an adjuvant to improve vaccine-induced T-cell mediated immunity. Here we show that including CD137L in an mRNA vaccine significantly boosted T-cell responses, but not in a protein vaccine. Furthermore, CD137L-containing vaccines induced lower antibody responses. These findings support that CD137L may boost the efficacy of T-cell-based mRNA vaccines.

  • Open Access

    Dengue virus 2 lacking N153 glycosylation displayed enhanced recognition by neutralizing antibodies

    by Guntur Fibriansah, Thiam-Seng Ng, Xin-Ni Lim, Joeshua W. S. Ng, Aaron W. K. Tan, Donald Heng Rong Ting, Gavin R. Screaton, James E. Crowe, Sylvie Alonso, Shee-Mei Lok

    Deglycosylated (N153Q) dengue virus (DENV) mutant shows attenuated infection in a mouse model, mainly due to its increased antibody susceptibility. This is consistent with the neutralization assay showing human monoclonal antibodies 2D22 and C10 are more potent towards the mutant than the wild-type (WT) virus. Here, we compared the cryoEM structures of WT and mutant viruses complexed with these Fabs at 37 °C (2.7–3.2 Å resolution). We observed increased occupancies for both Fabs on the mutant virus, suggesting higher accessibility of epitopes that were previously blocked by glycosylation. Using biolayer interferometry, we showed that at 30 °C, the antibodies exhibited a slower binding rate with the mutant than with WT virus, along with a slower dissociation rate. However, at 37 °C, the affinities of both antibodies for DENV2 WT and N153Q increased significantly. N153Q mutant might be a good vaccine candidate, as important epitopes are made more accessible for stimulating highly potent antibodies.

  • Open Access

    Dengue virus 2 lacking N153 glycosylation displayed enhanced recognition by neutralizing antibodies

    by Guntur Fibriansah, Thiam-Seng Ng, Xin-Ni Lim, Aaron W.K. Tan, Donald Heng Rong Ting, Gavin R. Screaton, James E. Crowe, Sylvie Alonso, Shee-Mei Lok

    Deglycosylated (N153Q) dengue virus (DENV) mutant shows attenuated infection in a mouse model, mainly due to its increased antibody susceptibility. This is consistent with the neutralization assay showing human monoclonal antibodies 2D22 and C10 are more potent towards the mutant than the wild-type (WT) virus. Here, we compared the cryoEM structures of WT and mutant viruses complexed with these Fabs (2.7-3.2 Å resolution). We observed increased occupancies for both Fabs on the mutant virus, suggesting higher accessibility of epitopes that were previously blocked by glycosylation. Using biolayer interferometry, we showed although the Fabs have slower binding rate to the mutant than WT virus, they also have slower dissociation rate. The slow dissociation rate might contribute to higher Fab occupancies, as once bound, they remain associated with the virus. N153Q mutant might be a good vaccine candidate, as important epitopes are made more accessible for stimulating highly potent antibodies.

  • Open Access

    A high dimensionality approach reveals immunopathogenic responses driving severe pediatric acute respiratory distress syndrome

    by Judith Ju Ming Wong, Herng Lee Tan, Clare Wei Tian Foo, Nicholas Kim Huat Khoo, Yik-Lam Cho, Su Li Poh, Martin Wasser, Sharifah Hazirah, Jing Yao Leong, Yee Hui Mok, et al.

    Mechanisms underlying paediatric acute respiratory distress syndrome (PARDS) remain poorly understood, limiting advances in diagnosis and treatment. To address this, we conduct a high-dimensional, multi-omics analysis of paired pulmonary and blood samples from children with PARDS and age-matched controls. Our approach includes transcriptomics, proteomics, flow and mass cytometry, and single-cell RNA sequencing, with further validation using cytokine assays and in vitro models. Severe PARDS is characterised by three convergent immune abnormalities; Pulmonary CD8 + T cells display an interferon-driven cytotoxic profile, with exhaustion and apoptosis genes; Pulmonary T cells and myeloid cells exhibit strong interferon-stimulated gene expression; Distinct macrophage subsets show high interferon but suppressed IL-1 pathway genes, associated with impaired leukocyte chemotaxis, phagocytosis, and M1-polarization. This is mirrored by reduced pulmonary IL-1α/β and elevated IFN-γ. The systemic IL-1 signature is similarly dampened, while interferon responses are compartmentalised to the lung. Using an in vitro model, IFN-γ priming is shown to suppress TLR7-induced IL-1 β production through transcriptional inhibition of downstream inflammatory pathways, recapitulating the immune signature observed in patients. Our results reveal interferon-driven immune dysregulation and IL-1 suppression as central features of severe PARDS, highlighting parallels and differences from adult ARDS and underscoring the need for paediatric-specific therapeutic strategies.


  • Author Correction: Enterovirus-A71 exploits peripherin and Rac1 to invade the central nervous system

    by Ze Qin Lim, Qing Yong Ng, Yukei Oo, Justin Jang Hann Chu, Shi Yan Ng, Siu Kwan Sze, Sylvie Alonso

  • Open Access

    Intranasal DC-targeting vaccine booster elicits durable and cross-clade protective immunity against sarbecoviruses in mice

    by Nicholas You Zhi Cheang, Wee Chee Yap, Kirsteen McInnes Tullett, Xinlei Qian, Peck Szee Tan, Kiren Purushotorman, Wan Yi Tan, Shirley Yun Yan Mah, Paul Anthony Macary, Chee Wah Tan, et al.

    Short-lived, clade-specific immune responses with limited mucosal priming are limitations of current COVID-19 mRNA vaccines. We have developed a nasal booster vaccine candidate that induced robust, sustained, cross-clade, systemic, and mucosal protective immunity. Two recombinant Clec9A-specific monoclonal antibodies fused to the receptor binding domain (RBD) from Omicron XBB.1.5 and SARS-CoV-1 were generated. In Comirnaty mRNA–vaccinated mice, boosting with both constructs combined (Clec9A OMNI ) induced cross-clade neutralizing antibodies and T cell responses that were greater in magnitude and more sustained compared with bivalent Comirnaty (BC) mRNA vaccine booster. Persistence of RBD-specific follicular helper CD4 + T cells, germinal center B cells, and long-lived plasma cells that facilitated affinity maturation correlated with detection of triple cross-reactive B cells binding the RBDs of ancestral SARS-CoV-2, XBB.1.5, and SARS-CoV-1. Remarkably, intranasal boosting with Clec9A OMNI elicited robust and durable immunity across the upper and lower airways while concurrently boosting the systemic immunity to levels matching or exceeding those from systemic boosting. Correspondingly, Clec9A OMNI nasal booster conferred superior protection against SARS-CoV-2 challenge compared with BC mRNA booster, with undetectable viral titers in the respiratory tract. Hence, Clec9A OMNI is a promising nasal booster vaccine candidate that has the potential to mitigate pandemic threats from emerging sarbecoviruses.


  • Open Access

    Glycans on non-structural protein 1 prevent premature T-cell mediated dengue virus clearance

    by Fakhriedzwan Idris, Justin Seng Geap Ooi, Donald Heng Rong Ting, Eunice Tze Xin Tan, Corrine Wan, Peter I Benke, Jan K Marzinek, Jack M Copping, Qin Hui Li, Lu Yi Ng, et al.

    Non-structural protein 1 (NS1) of dengue virus (DENV) harbours two conserved N-glycosylation sites at positions 130 and 207, whose biological roles have remained elusive. Using a clinically relevant mouse model of severe dengue, we showed that DENV that lacked N207 glycans on NS1 was significantly attenuated, and this phenotype was dominant over wild-type virulent DENV. Mice infected with this mutant exhibited accelerated viral clearance, milder lymphopenia and more functional DENV-specific CD8 + T cells. Bulk and single-cell RNA sequencing, cytokine measurements and immune-phenotyping revealed blunted innate inflammatory responses early post-infection, which correlated with reduced PD-L1 expression on innate immune cells and reduced PD-1 + T-cells in mice infected with de-glycosylated DENV. PD-1 blockade demonstrated the involvement of premature T-cell apoptosis through the PD-L1/PD-1 axis in DENV pathogenesis. Collectively, our findings support that N207-de-glycosylated NS1 inhibits early inflammatory responses, which restricts PD-L1 upregulation on innate immune cells, which in turn limits PD-L1/PD-1 mediated T-cell apoptosis. Our study uncovers a novel immune evasion strategy and identifies PD-L1/PD-1 as a novel mechanism of dengue immunopathogenesis.


  • Open Access

    N153-linked glycans on envelope protein protect orthoflaviviruses from antibody-mediated clearance

    by Donald Heng Rong Ting, Jan Kazimierz Marzinek, Corrine Wan, Raghuvamsi V. Palur, Fakhriedzwan Idris, Eunice Tze Xin Tan, Wei Teng Clara Koh, Xin Ni Lim, Tun-Linn Thein, Cheer Vee Lim, et al.

    The envelope (E) protein of dengue virus (DENV) is glycosylated at two highly conserved asparagine (N) sites (N67 and N153). The role and importance of these N-linked glycans in DENV pathogenesis has been elusive. Here, we report the critical role of N153-linked glycans on E protein in preventing antibody-mediated viral clearance. A DENV2 mutant lacking N153-linked glycans (N153Q mutant) was engineered and found to be mildly impaired in vitro but drastically attenuated in a symptomatic mouse model of severe dengue, as evidenced by accelerated viral clearance. In B cell-deficient mouse models, N153Q mutant displayed parental virulence and viremia profile. Homologous and heterologous passive transfers of purified IgM from infected B cell-proficient mice into B cell-deficient mice demonstrated the role of N153Q-specific IgM in N153Q attenuation and accelerated clearance, while WT DENV was unaffected by IgM from both WT- and N153Q-infected mice. Furthermore, in vitro neutralization assay supported that the accelerated clearance of N153Q mutant in mice was mediated by non-neutralizing IgM. Furthermore, using plasma samples from convalescent dengue patients and monoclonal antibodies, in vitro neutralization assays showed that N153Q virus was more susceptible than WT to IgG-mediated neutralization. Glycoproteomics combined with molecular dynamics (MD) simulations revealed that glycan composition on E protein influenced IgG binding. Our findings were extended to all DENV serotypes and ZIKV, hence supporting that the N153 glycans-mediated immune evasion strategy is conserved across orthoflaviviruses.


  • Open Access

    Elevated Plasma Angiopoietin-like 4 Protein Levels in Adult Patients with Dengue

    by Win Khaing, Suk Hiang Lau, Tun-Linn Thein, Nguan Soon Tan, Sylvie Alonso, Shawn Vasoo, Po Ying Chia, David Chien Boon Lye, Yee Sin Leo, Vincent T. K. Chow

    Dengue virus infection can cause severe complications due to vascular leakage. Angiopoietin-like protein 4 (ANGPTL4) regulates vascular permeability, but its role in dengue pathogenesis is unclear. This study investigated the association between plasma ANGPTL4 levels and dengue severity in Singapore adults. Plasma samples from 48 dengue patients (24 severe and 24 non-severe) during acute and convalescent phases were selected from the prospective COhort study on progression of DENgue severity in Singapore adults (CODEN) cohort. The CODEN was conducted at the National Centre for Infectious Diseases, Tan Tock Seng Hospital, from June 2016 to January 2020. ANGPTL4 levels were measured and compared to 152 healthy controls. Logistic regression assessed the relationship between plasma ANGPTL4 concentrations and disease severity. There were no statistically significant differences in ANGPTL4 levels between severe and non-severe dengue patients during acute (677.4 vs. 909.1 pg/mL, p = 0.4) or convalescent phases (793.7 vs. 565.6 pg/mL, p = 0.96). Plasma ANGPTL4 levels were significantly elevated during acute dengue (4634.3 pg/mL) versus healthy controls (907.4 pg/mL), declining during convalescence. Compared to the lowest tertile, the adjusted odds ratios for severe dengue were 0.36 (95%CI: 0.08–1.65, p = 0.190) for medium tertile and 0.57 (95%CI: 0.13–2.49, p = 0.456) for high tertile. Among patients with high ANGPTL4 levels (>5000 pg/mL), 36.4% developed severe complications, including significant plasma leakage. Plasma ANGPTL4 levels were significantly higher in dengue patients than controls, suggesting its potential as a biomarker, which warrants future detailed investigations. Larger prospective studies with serial sampling, including pediatric populations, may clarify the role of ANGPTL4 in severe dengue.


  • Open Access

    Enterovirus-A71 preferentially infects and replicates in human motor neurons, inducing neurodegeneration by ferroptosis

    by Wai Hon Chooi, Winanto, Yingying Zeng, Cheryl Yi-Pin Lee, Ze Qin Lim, Pradeep Gautam, Justin Jang Hann Chu, Yuin-Han Loh, Sylvie Alonso, Shi-Yan Ng

    Enterovirus A71 (EV-A71) causes Hand, Foot, and Mouth Disease and has been clinically associated with neurological complications. However, there is a lack of relevant models to elucidate the neuropathology of EV-A71 and its mechanism, as the current models mainly utilize animal models or immortalized cell lines. In this study, we established a human motor neuron model for EV-A71 infection. Single cell transcriptomics of a mixed neuronal population reveal higher viral RNA load in motor neurons, suggesting higher infectivity and replication of EV-A71 in motor neurons. The elevated RNA load in motor neurons correlates with the downregulation of ferritin-encoding genes. Subsequent analysis confirms that neurons infected with EV-A71 undergo ferroptosis, as evidenced by increased levels of labile Fe2+ and peroxidated lipids. Notably, the Fe2+ chelator Deferoxamine improves mitochondrial function and promotes survival of motor neurons by 40% after EV-A71 infection. These findings deepen understanding of the molecular pathogenesis of EV-A71 infection, providing insights which suggest that improving mitochondrial respiration and inhibition of ferroptosis can mitigate the impact of EV-A71 infection in the central nervous system.